98%
921
2 minutes
20
The formation and progression of microvascular thrombosis are critical mechanisms underlying many vascular-related diseases. Therefore, replicating the microvascular blood flow environment in vitro and investigating the mechanisms of microvascular thrombosis formation are highly significant. In recent years, microfluidic chip technology has been extensively applied in in vitro research for its capability to systematically and comprehensively replicate the complex processes of microvascular thrombosis in laboratory settings. This review systematically examines the development and applications of microfluidic chip technology in microvascular thrombosis research. It begins with a brief summary of the technical features of microfluidic chip technology, followed by a detailed discussion of its applications in constructing in vitro microvascular models, investigating thrombosis mechanisms, and evaluating antithrombotic drug efficacy. Finally, the review summarizes the current research progress and discusses potential directions for future development. This review also systematically explains the breakthrough contribution of microfluidic chips from the perspective of engineering bionics and provides new insights for the pathological research and clinical management of microvascular thrombosis: constructing a high-precision physiological simulation system through bionic topology design and dynamic fluid regulation to achieve high-precision reconstruction of vascular dynamic microenvironment; based on the systems-level dynamics analysis, the dynamic evolution law of multi-factor synergy in the process of thrombosis is revealed; construct a drug-response evaluation system and establish a transformation bridge from micro-mechanism to clinical intervention. In summary, this review is expected to accelerate the development of targeted therapies and diagnostic tools for microvascular thrombosis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00604-025-07239-1 | DOI Listing |
J Reconstr Microsurg
September 2025
Department of Plastic and Reconstructive Surgery, MedStar Georgetown University Hospital, Washington, District of Columbia, United States.
The use of vasopressors during microsurgical reconstruction is debated. Their effect on the comorbid lower extremity (LE) wound population is unstudied. This study characterizes the impact of intraoperative vasopressor use in LE free tissue transfer (FTT) for limb salvage.
View Article and Find Full Text PDFInt Ophthalmol
September 2025
Ophthalmology Department, Faculty of Medicine, Menoufia University, Shebin El-Kom, 32511, Menoufia, Egypt.
Purpose: To evaluate the role of optical coherence tomography angiography (OCTA) in differentiating ischemic and non-ischemic central retinal vein occlusion (CRVO).
Methods: This prospective observational study included 72 eyes with CRVO (36 ischemic, 36 non-ischemic), all presenting with macular edema. Participants underwent clinical evaluation, fundus fluorescein angiography (FFA), and OCTA imaging.
BMJ Case Rep
September 2025
Clinical Immunology and Rheumatology, King George's Medical University, Lucknow, Uttar Pradesh, India
Antiphospholipid syndrome (APS) is characterised by arterial, venous or microvascular thrombosis and/or pregnancy morbidity. Bone infarct, or avascular necrosis (AVN), is seen in up to 2.9% of patients with primary and secondary APS.
View Article and Find Full Text PDFAnn Med Surg (Lond)
September 2025
Department of Biomedical and Laboratory Science, Africa University, Mutare, Zimbabwe.
Thrombotic microangiopathies (TMAs) encompass a diverse group of syndromes marked by microvascular thrombosis, thrombocytopenia, and organ injury, primarily affecting the kidneys and central nervous system. While the etiologies differ-ranging from genetic mutations to infectious and autoimmune triggers-a unifying pathogenic mechanism is endothelial dysfunction. Recent advances have illuminated the pivotal role of cytokine dysregulation in initiating and sustaining this vascular injury.
View Article and Find Full Text PDFInt J Mol Sci
August 2025
Postgraduate Program of Health Sciences, School of Medicine and Life Sciences, Pontifical Catholic University of Paraná-PUCPR, Rua Imaculada Conceição, 1155-Prado Velho, Curitiba 80215-901, PR, Brazil.
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, spread rapidly across the globe in 2020, with most countries experiencing two distinct waves of infection. In Brazil, the second wave was marked by the emergence of the P.1 (Gamma) variant, which disproportionately affected younger individuals and was associated with increased mortality.
View Article and Find Full Text PDF